Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Safety and dose-escalation study of a targeted oncolytic adenovirus, suratadenoturev (OBP-301), in patients with refractory advanced liver cancer: Phase I clinical trial.
Authors
Jeong Heo
Department of Internal Medicine, Pusan National University College of Medicine and Medical Research Institute, Pusan National University Hospital, Busan, South Korea
Jeong Heo , Ja-Der Liang , Chang Won Kim , Hyun Young Woo , I-Lun Shih , Tung-Hung Su , Zhong-Zhe Lin , Stanley Chang , Yasuo Urata , Pei-Jer Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02293850
DOI
10.1200/JCO.2022.40.4_suppl.459
Abstract #
459
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors.
First Author: Toshio Shimizu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of combining genotype-guided irinotecan (Iri) with 5FU, leucovorin (LV), oxaliplatin (Ox), and docetaxel (Tax) (gFOLFOXIRITAX): The I-FLOAT phase 1 dose-escalation study for advanced upper GI cancers.
First Author: Koosha Paydary
Poster
2019 ASCO Annual Meeting
A first-in-human, multicenter, open label, phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of intravenously administered ATOR-1015.
First Author: Jeffrey Yachnin
Poster
2017 ASCO Annual Meeting
A phase I dose escalation study of SCB01A, a micro-tubular inhibitor with vascular disrupting activity, in patients with advanced solid tumors refractory to standard therapy.
First Author: Nai-Jung Chiang